首页> 外国专利> TARGETED ONCOLYTIC ADENOVIRUS FOR TREATMENT OF HUMAN TUMORS, CONSTRCUTION METHOD AND APPLICATION THEREOF

TARGETED ONCOLYTIC ADENOVIRUS FOR TREATMENT OF HUMAN TUMORS, CONSTRCUTION METHOD AND APPLICATION THEREOF

机译:靶向靶向治疗人类肿瘤的腺病毒,构建方法及其应用

摘要

An oncolytic adenovirus vector and its potential application in cancer treatment and vaccination. The inventive vector (named Ad-TD-hIL12) is derived from the human adenovirus group C type 5, more particularly including deletion of three adenovirus genes E1A-CR2, E1B19K and E3gp-19K, and a fused cDNA sequence of p35 and p40 subunit of human IL12 placed under the control of the E3gp-19K promoter. The invention also includes a method to construct the triple gene-deleted vector (Ad-TD). The Ad-TD-hIL12 and Ad-TD-shIL12 (with a short p40 sequence of human IL 12) vectors can be used as targeted, genetically engineered agents for treatment of various solid tumors, via not only intratumoral injection, and also in intraperitoneal injection, without causing significant side effects, showing a superior antitumor efficacy and safety.
机译:溶瘤腺病毒载体及其在癌症治疗和疫苗接种中的潜在应用。本发明的载体(命名为Ad-TD-hIL12)衍生自人类5型腺病毒,更特别地包括三个腺病毒基因E1A-CR2,E1B19K和E3gp-19K的缺失,以及p35和p40亚基的融合cDNA序列。被置于E3gp-19K启动子控制下的人IL12的表达。本发明还包括构建缺失三重基因的载体(Ad-TD)的方法。 Ad-TD-hIL12和Ad-TD-shIL12(具有短的人IL 12 p40序列)载体可用作靶向基因工程药物,不仅可以通过瘤内注射,而且可以通过腹膜内注射治疗各种实体瘤注射,而不会引起明显的副作用,显示出优异的抗肿瘤功效和安全性。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号